Efficacy and Outcomes After Vasopressin Guideline Implementation in Septic Shock
|
|
- Sherman Johnston
- 5 years ago
- Views:
Transcription
1 669163AOPXXX / Annals of PharmacotherapyWu et al research-article2016 Research Report Efficacy and Outcomes After Vasopressin Guideline Implementation in Septic Shock Annals of Pharmacotherapy 2017, Vol. 51(1) The Author(s) 2016 Reprints and permissions: sagepub.com/journalspermissions.nav DOI: / aop.sagepub.com Janet Y. Wu, PharmD 1, Joanna L. Stollings, PharmD, FCCM, BCPS, BCCCP 1, Arthur P. Wheeler, MD 2,, Matthew W. Semler, MD, MSc 2, and Todd W. Rice, MD, MSc 2 Abstract Background: In septic shock, the dose of norepinephrine (NE) at which vasopressin (AVP) should be added is unknown. Following an increase in AVP price, our medical intensive care unit (MICU) revised its vasopressor guidelines to reserve AVP for patients requiring greater than 50 µg/min of NE. Objective: The purpose of this study is to compare efficacy and safety outcomes for patients admitted before the guideline revision with those for patients admitted after the revision. Methods: This was a single-center, retrospective cohort study of patients admitted to Vanderbilt University Medical Center from November 1, 2014, to November 30, Before June 1, 2015, the vasopressor guidelines recommended initiation of AVP for patients requiring 10 µg/min of NE or greater. After June 1, 2015, the guidelines recommended initiation of AVP at a NE dose of 50 µg/min or greater. Results: Time to achieve goal mean arterial pressure (MAP) was shorter in the postintervention group (2.0 vs 1.3 hours; P = 0.03) in univariate analysis but not after adjusting for prespecified confounders. Incidence of new arrhythmias was similar between the 2 groups (14.9% vs 10.9%; P = 0.567). In multivariable analysis accounting for baseline severity of illness, admission after the revision was associated with decreased 28-day mortality (odds ratio = 0.34; 95% CI = ; P = 0.004). Conclusions: Use of a vasopressor guideline restricting AVP initiation in septic patients to those on at least 50 µg/min of NE appeared to be safe and did not affect the time to reach goal MAP. Keywords adrenergic agonists, critical care, sympathomimetics, sepsis, clinical research Background Norepinephrine (NE) and vasopressin (AVP) are commonly used vasopressors for patients in septic shock. The 2012 Surviving Sepsis Campaign guidelines recommend NE as the vasopressor of choice and adding AVP to increase mean arterial pressure (MAP) or to decrease NE dosage. 1 In a study of patients with catecholamine-resistant vasodilatory shock, AVP was initiated in patients who were volume refractory and required NE doses exceeding 0.5 µg/kg/min. The authors found that patients receiving both AVP and NE performed better hemodynamically compared with patients receiving only NE. 2 In contrast, Micek et al 3 showed that patients who received NE and AVP had significantly higher mortality rates than patients on NE alone. To complicate matters further, a maximum dose of NE has not been determined. Doses ranging from 0.2 to 5 µg/kg/min have been used in studies, although higher doses ( µg/kg/min) are associated with a risk of extreme vasoconstriction and tissue hypoperfusion. 4-6 The Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock (VASST) trial compared NE with NE plus AVP and found no significant difference in 28-day mortality. The researchers found that in the defined stratum of less-severe septic shock, patients who received AVP had a lower mortality rate compared with patients who received NE (26.5% vs 35.7%, P = 0.05). 7 However, the study was not powered to detect this outcome, and some clinicians have called into question whether AVP should be initiated in patients receiving 15 µg/min or less of NE. 1 Vanderbilt University Medical Center, Nashville, TN, USA 2 Vanderbilt University School of Medicine, Nashville, TN, USA Deceased. Corresponding Author: Joanna L. Stollings, Department of Pharmaceutical Services, Vanderbilt University Medical Center, 1211 Medical Center Drive BUH-131 Nashville, TN 37232, USA. joanna.stollings@vanderbilt.edu
2 14 Annals of Pharmacotherapy 51(1) In 2013, a vasopressor guideline was implemented in the medical intensive care unit (MICU) at our institution that recommended (1) no maximum dose of NE and (2) that AVP 0.04 U/min be added once patients reached a NE dose of 10 µg/min. This guideline also recommended discontinuing NE first. A study comparing the preguideline implementation group with the postguideline implementation group found no difference in the time to reach goal MAP or the incidence of arrhythmias. However, the mean dose of vasopressor at which another catecholamine vasopressor was added increased significantly between the control and intervention groups. 8 With a large increase in the price of AVP, new guidelines were implemented in the MICU in 2015 to supplement NE with AVP 0.04 U/min only when patients required doses of 50 µg/min of NE. Contrary to the original guideline, the new one recommended discontinuing AVP first. Given the large increase in price of AVP and lack of robust data to support addition of AVP at low doses of NE, we hypothesized that delay in addition of AVP until patients were receiving 50 µg/min of NE would not result in a change in time to reach goal MAP. Methods Study Design and Participants We conducted a quasiexperimental cohort study using a pre-post intervention design to evaluate the effectiveness of the AVP-sparing guideline revision. This study took place between November 1, 2014, and November 30, 2015, in the MICU. Patients were identified through retrospective chart review and included if they were admitted to the MICU and received NE therapy for septic shock for at least 6 hours. Exclusion criteria were pregnancy, other concomitant vasopressors (epinephrine, phenylephrine, or dopamine), receipt of vasopressors at an outside hospital prior to transfer, NE or AVP initiated outside of the MICU, receipt of NE at doses 50 µg/min, and receipt of vasopressors for an indication other than septic shock. The Vanderbilt University Institutional Review Board approved this study with a waiver of informed consent. Interventions Vasopressor guidelines at our institution were developed in April 2013, which recommended initial NE use without a maximum dose followed by AVP once patients reached NE 10 µg/min. These guidelines recommended discontinuing NE first before stopping AVP and did not place any restrictions on the use of other vasopressors such as epinephrine and phenylephrine. Patients in the preintervention group were managed using the 2013 vasopressor guidelines and were admitted from November 1, 2014, to June 30, Patients included in the preintervention group received NE <50 µg/min with AVP 0.04 U/min. With the large increase in the price of AVP, these vasopressor guidelines were revised in June 2015 to recommend initial NE use without a maximum dose, AVP initiation once NE reached 50 µg/min, and discontinuation of AVP before NE. Patients in the postintervention group were managed using the 2015 vasopressor guidelines, the AVP-sparing strategy, and were admitted from July 1 to November 1, Patients included from the postintervention group received NE < 50 µg/min without AVP. The primary objective of this study was to determine if delay in the start of AVP until patients were receiving 50 µg/min of NE changed time to reach goal MAP of 65 mm Hg. Statistical Analysis Data were extracted from the electronic medical records for all patients who met inclusion criteria during the 1-year study period. Flowsheet data were used for the majority of data collection, including doses of NE. Categorical data were analyzed using the χ 2 test and are reported as numbers and percentages. Continuous data were analyzed using the Mann-Whitney U test and reported as median and interquartile range. A linear regression was conducted to examine the association between the pre-post intervention and the outcomes of hospital length of stay and ICU length of stay after accounting for baseline APACHE (Acute Physiologic Chronic Health Evaluation) II score and NE dose. A logistic regression was conducted with the same variables for the outcome of 28-day mortality. A Cox proportional hazard model was developed to examine the relationship between the pre-post intervention and the time until goal MAP was achieved after accounting for prespecified confounders. Statistical analyses were performed with IBM SPSS Statistics, version 23. Results Over the study period, data from 635 patients receiving NE and AVP were reviewed. A total of148 patients were included in the study after 487 patients met the exclusion criteria. Figure 1 illustrates reasons for exclusion. Baseline Demographics Patients in the preintervention and postintervention periods were similar at baseline except for higher APACHE II score (23 vs 18; P = 0.001) and increased prevalence of cardiogenic shock (10.8% vs 2.7%; P = 0.049) in the preintervention group (Table 1).
3 Wu et al 15 was associated with both hospital (adjusted odds ratio [OR] = 10; 95% CI = ; P < ) and ICU length of stay (adjusted OR = 1.99; 95% CI = ; P < ). Mortality at 28 days was significantly higher in the preintervention group at 51% compared with 28% in the postintervention group (Table 2). Logistic regression showed an association between the postintervention group and lower 28-day mortality after adjusting for the type of intervention received, APACHE II score, and NE dose at initiation (adjusted OR = 0.34, 95% CI = , P = 0.004; Table 2). Finally, given that AVP was not used in the postintervention phase, our institution net a cost avoidance of $ compared with the preintervention group. Figure 1. Derivation of the study cohort. Abbreviations: AVP, vasopressin; MICU, medical intensive care unit; NE, norepinephrine. Outcomes In unadjusted analysis, the time to reach goal MAP was longer in the preintervention group than the postintervention group (2 vs 1.3 hours, P = 0.030). After adjusting for age, APACHE II score, receipt of corticosteroids, initiation of dialysis, and the NE dose at initiation in a Cox proportional hazard model, however, there was no difference in the time to reach goal MAP between patients in the 2 groups (Figure 2). The median NE dose at initiation was 10 µg/min (0.106 µg/kg/min) in the preintervention group versus 5 µg/min (0.068 µg/kg/min) in the postintervention group (P < 0.001). The median maximum NE dose was 24 (0.325 µg/kg/min) versus 11 µg/min (0.145 µg/kg/min; P < 0.001). The dose of NE at which AVP was initiated in the preintervention group was 18 µg/min (0.233 µg/kg/min). The duration of NE was a median of 34.3 and 26.0 hours preintervention and postintervention, respectively (P = 0.094). The duration of AVP in the preintervention group was a median of 28.8 hours, and the duration of concomitant NE and AVP was 25.5 hours. More patients in the preintervention group required dialysis compared with the postintervention group (25.7% vs 8.1%, P = 0.004). There were no differences between the 2 groups with regard to receipt of concomitant medications, including corticosteroids and inotropes. Concomitant corticosteroids were administered in 16 patients (21.6%) in the preintervention group compared with 15 patients (20.3%) in the postintervention group (P = 0.840). The maximum lactate levels were 3.2 and 1.3 mmol/l, respectively (P < 0.001), and there was no difference with regard to heart rate or incidence of new arrhythmias (14.9% vs 10.9%, P = 0.567). There was no difference between the 2 groups in regard to hospital and ICU length of stay. Linear regression showed that the starting NE dose Discussion In this retrospective cohort study using a pre-post intervention design, initiation of AVP at a NE dose of at least 50 µg/ min rather than 10 µg/min did not appear to be associated with a difference in the time to reach goal MAP. Reserving AVP for septic shock patients requiring higher NE doses also appeared safe with regard to new arrhythmias, ICU and hospital length of stay, and in-hospital mortality. The Surviving Sepsis Campaign guidelines recommend achieving a goal MAP of at least 65 mm Hg during the first 6 hours of resuscitation. 1 Persistent hypotension, defined as MAP of less than 65 mm Hg, is associated with poor outcomes, such as increased mortality and need for renal replacement therapy. 9,10 Dunser et al 10 conducted a retrospective cohort study to evaluate the association between arterial blood pressure during the first 24 hours and mortality in sepsis. They found that one or more hypotensive episodes (MAP < 60 mm Hg) was associated with an almost 3-fold increased risk of death (OR = 2.96; 95% CI = ; P = 0.04). Despite extensive study, the best approach to vasopressor use during septic shock remains undefined. In our study, using NE as an initial agent and reserving the addition of AVP for patients requiring at least 50 µg/min of NE appeared to be as safe as earlier AVP initiation with regard to MAP achieved, incidence of arrhythmias, and clinical outcomes. Left untreated, septic shock can lead to organ dysfunction such as renal failure. AVP has been suggested to not only decrease the dose of NE, but also increase urine output and creatinine clearance and reduce the progression to renal failure A retrospective case series evaluated the effects of AVP on hemodynamic and renal function and found that urine output increased by 79% 4 hours after starting AVP (P = 0.002). However, further increases were not significant at 24- or 48-hour time points. 11 A post hoc analysis of the VASST trial, stratifying patients according to the modified RIFLE criteria, found that AVP decreased the worsening of renal failure and need for dialysis by almost 2-fold
4 16 Annals of Pharmacotherapy 51(1) Table 1. Baseline Demographics. Preintervention (n = 74) Postintervention (n = 74) P Value Age (years) a 57.5 ( ) 58 ( ) Sex (male) 40 (54.1%) 33 (44.6%) Weight (kg) a 78.2 ( ) 72.7 ( ) Race White 61 (82.4%) 58 (78.4%) Black 12 (16.2%) 11 (14.9%) Asian 0 (0%) 2 (2.7%) Unknown 1 (1.4%) 3 (4.1%) Past medical history Dialysis 1 (1.4%) 6 (8.1%) Liver disease 12 (16.2%) 13 (17.6%) Arrhythmia 11 (14.9%) 8 (10.8%) CAD 15 (20.3%) 13 (17.6%) CHF 11 (14.9%) 20 (27.0%) COPD 12 (16.2%) 16 (21.6%) Cancer 20 (27.0%) 21 (28.4%) Immunosuppressed 10 (13.5%) 13 (17.6%) Where admitted from Outside hospital 39 (52.7%) 28 (37.8%) Emergency department 35 (47.3%) 43 (58.1%) Floor 0 (0%) 3 (4.1%) Infection source b Pneumonia 30 (40.5%) 28 (37.8%) Intra-abdominal 14 (18.9%) 13 (17.6%) Line infection 1 (1.4%) 3 (4.1%) Urinary 16 (21.6%) 13 (17.6%) Skin and soft tissue 6 (8.1%) 13 (17.6%) Other 4 (5.4%) 2 (2.7%) Unknown 8 (10.8%) 8 (10.8%) Type of shock b Septic 74 (100.0%) 74 (100.0%) Cardiogenic 8 (10.8%) 2 (2.7%) Hypovolemic 4 (5.4%) 7 (9.5%) Neurogenic 0 (0%) 0 (0%) APACHE II a 23 ( ) 18 (14-26) Abbreviations: APACHE, Acute Physiologic Chronic Health Evaluation; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disorder. a Median (interquartile range). b Patient could have more than 1 infection source and more than 1 type of shock. (P = 0.03 and P = 0.02, respectively) among patients with mild renal injury. 13 However, the finding of the beneficial effects of AVP on renal function has not been universal. A recent randomized controlled trial evaluated kidney failure free days in sepsis patients receiving either AVP or NE. The results from this trial found no difference in the distribution of kidney failure free days between the 2 groups (P = 0.88) or rate of renal replacement therapy (AVP, 25.4%; NE, 35.3%; P = 0.73). 14 In our study, patients who did not receive AVP had higher urine output compared with patients who did receive AVP, although this was only significant at the time of and 6 hours after NE initiation. Furthermore, significantly more patients in the preintervention group required dialysis than patients in the postintervention group (25.7% and 8.1%, respectively; P = 0.004). Cox proportional hazard analysis adjusting for differences in dialysis requirement was utilized to account for the potential effects of AVP on renal function (Figure 2). Adverse effects of AVP reported in studies include mesenteric ischemia, myocardial ischemia, digital ischemia, skin necrosis, and hyponatremia. 11,12,15-18 However, most of these studies were relatively small and unblended, so the true risks of AVP infusion remain unknown. Because of the retrospective nature of our study, it was not reasonable to
5 Wu et al 17 Figure 2. Time required to achieve goal blood pressure in each study group. In a Cox proportional hazard model adjusting for pre-specified covariates of age, APACHE II score, receipt of corticosteroids, dialysis, and NE dose at initiation, there was no difference between the pre-intervention (AVP) and postintervention (no AVP) groups in the time required to achieve a MAP of at least 65 mmhg (P = 0.07). collect data on rates of ischemia. Instead, we used maximum lactate level as a marker of ischemia and found that patients who received NE and AVP had a significantly higher lactate level compared with patients who only received NE (3.2 vs 1.3, P < 0.001). Although NE is associated with arrhythmias, the rate of development of new arrhythmias was low and did not differ between each group (14.9% vs 10.8%, P = 0.567). There was also no difference between median heart rates at any time point throughout the study. Recent studies have suggested that there may be a potential interaction between AVP and corticosteroids and that treatment with the combination may result in higher plasma levels of AVP and improved outcomes A post hoc substudy of the VASST trial found that there was a significant interaction between receipt of AVP infusion and corticosteroid treatment (P = 0.008). There was also an association with decreased mortality in patients who received corticosteroids and AVP compared with NE (35.9% vs 44.7%, P = 0.03). In patients who did not receive corticosteroids, receipt of AVP was associated with increased mortality compared with receipt of NE (33.7% vs 21.3%, P = 0.06). 19 A subsequent small prospective trial was conducted to evaluate the potential interaction between AVP and corticosteroids. Patients in the corticosteroid group required a shorter duration (3.1 days, 95% CI = ) and lower total dose of AVP (ratio = 0.47; 95% CI = ) when compared with the placebo group. 22 Although the difference between the receipt of corticosteroids in the 2 arms of our study was not significant (21.6% vs 20.3%, P = 0.840), given the potential interaction between AVP and corticosteroids shown in the aforementioned trials, differences in receipt of corticosteroids were accounted for in the Cox proportional hazard model (Figure 2). With regard to clinical outcomes, results from the VASST trial showed no difference in mortality in patients who were randomized to receive NE or AVP (39.3% vs 35.4%, P = 0.26). In addition, there were no differences in ICU length of stay (16 vs 15 days, P = 0.14) or hospital length of stay (26 vs 27 days, P = 0.23). 7 Whereas the lengths of stay in our study were shorter than those in the VASST trial, no differences were found between our 2 groups. After adjusting for the type of intervention received, APACHE II score, and NE dose at initiation, linear regression showed that the NE dose was the only variable associated with hospital and ICU lengths of stay (P < ). There was a difference seen in mortality rates between patients who received AVP and patients who did not (51.4% vs 28.4%, P < 0.004), which remained even after multivariate regression analysis. Although these mortality findings are interesting, unlike the VASST trial, our study was not designed or powered for a mortality end point. To our knowledge, this is the only study that has evaluated time to reach goal MAP and safety outcomes after implementation of an AVP-sparing guideline. Moreover, a cost analysis showed that patients in the preintervention group received an average of 4 vials of AVP during the admission, resulting in a cumulative cost of $ Use of similar protocols at other institutions might be expected to result in substantial cost savings. However, our study also has some limitations. Given the retrospective nature of this study, it is possible that selection bias may have affected our findings. The preintervention group may have included sicker patients, as seen by the higher APACHE II score of 23 compared with 18. We were also unable to evaluate for guideline adherence in this study. The median dose of NE at which AVP was initiated in the preintervention cohort was 18 µg/min, which is higher than the protocol recommendation of initiating AVP at a NE dose of 10 µg/min. The use of AVP in the preintervention group may have been reserved for more critically ill patients, as observed by differences in variables such as the APACHE II scores. We attempted to account for this potential selection bias through multivariate analysis using the Cox proportional hazard model as well as through multiple linear and logistic regressions by accounting for the type of intervention received. Because this study was conducted in a large academic tertiary medical center, many patients are referrals from outside facilities (52.7% of patients in the preintervention group and 37.8% of patients in the postintervention group). Although patients who received vasopressors at an outside hospital were excluded, we were unable to
6 18 Annals of Pharmacotherapy 51(1) Table 2. Clinical Outcomes. Preintervention (n = 74) Postintervention (n = 74) P Value Adjusted OR 95% CI P Value Time to reach goal MAP (hours) a 2 ( ) 1.3 ( ) MAP (mm Hg) a At initiation of NE 56 (52-60) 56 (51-60) At initiation of AVP 61 (57-65) 6 hours 66 (60-74) 66 (60-71) hours 68 (63-74) 68 (63-73) hours 66 (61-73) 67 (62-74) hours 68 (62-74) 66 (62-74) hours 67 (63-73) 65 (62-73) hours 68 (63-73) 69 (62-76) hours 65 (62-73) 68 (64-73) hours 65 (62-68) 65 (61-73) Heart rate (bpm) a At initiation of NE 98 (81-114) 92 (79-108) At initiation of AVP 104 (84-118) 6 hours 98 (81-112) 91 (76-106) hours 97 (81-111) 90 (77-106) hours 95 (79-111) 89 (77-108) hours 100 (78-108) 94 (75-114) hours 99 (76-111) 95 (77-115) hours 98 (74-109) 91 (80-109) hours 94 (73-107) 95 (84-103) hours 98 (71-109) 91 (80-107) NE doses (µg/min) a Initiation 10.0 ( ) 5.0 ( ) <0.001 Maximum 24.0 ( ) 11.0 ( ) <0.001 At initiation of AVP 18.0 ( ) NE doses (µg/kg/min) a Initiation ( ) ( ) <0.001 Maximum ( ) ( ) <0.001 At initiation of AVP ( ) Duration (hours) a NE 34.3 ( ) 26.0 ( ) AVP 28.8 ( ) NE and AVP 25.5 ( ) Crystalloid intake at 6 hours a 2.0 ( ) 2.0 ( ) Urine output (ml/kg/h) a At initiation of NE 0.17 ( ) 0.29 ( ) At initiation of AVP 0.27 ( ) 6 hours 0.24 ( ) 0.41 ( ) hours 0.26 ( ) 0.42 ( ) hours 0.31 ( ) 0.32 ( ) hours 0.38 ( ) 0.38 ( ) hours 0.36 ( ) 0.28 ( ) hours 0.35 ( ) 0.51 ( ) hours 0.18 ( ) 0.49 ( ) hours 0.12 ( ) 0.44 ( ) Maximum lactate (mg/dl) a 3.2 ( ) 1.3 ( ) <0.001 Concomitant medications Steroids 16 (21.6%) 15 (20.3%) Dobutamine 1 (1.4%) 2 (2.7%) Milrinone 0 (0%) 1 (1.4%) (continued)
7 Wu et al 19 Table 2. (continued) Preintervention (n = 74) Postintervention (n = 74) P Value Adjusted OR 95% CI P Value Blood transfusions 34 (45.9%) 29 (39.2%) Cardiac arrest 7 (9.5%) 1 (1.4%) New arrhythmia Atrial fibrillation 8 (10.8%) 7 (9.5%) Ventricular fibrillation 0 (0%) 0 (0%) Ventricular tachycardia 3 (4.1%) 1 (1.4%) Cumulative AVP cost $ $0 Mechanical ventilation 36 (48.6%) 36 (48.6%) Dialysis 19 (25.7%) 6 (8.1%) Hospital length of stay a 9 (5-16) 11 (7-19) Pre-Post group APACHE II score NE dose initiation < ICU length of stay a 6 (4-9) 7 (4-11) Pre-Post group APACHE II score NE dose initiation < Day mortality 38 (51.4%) 21 (28.4%) Pre-Post group APACHE II score NE dose initiation Abbreviations: APACHE, Acute Physiologic Chronic Health Evaluation; AVP, vasopressin; ICU, intensive care unit; MAP, mean arterial pressure; NE, norepinephrine; OR, odds ratio. a Median (interquartile range). Multivariate analyses adjusted for the intervention, APACHE II score, and the NE dose at initiation, and values shown are ORs for the specific variables. collect data on fluid status and determine if patients were appropriately fluid resuscitated in those included. However, the median amount of crystalloids received within 6 hours of starting NE therapy was 2 L in both groups, suggesting that patients received the recommended 30-mL/kg crystalloid for septic shock. 1 Furthermore, this study was only conducted in the medical ICU, which limits the generalizability of the results of this study to other, non-medical ICUs. Finally, because of the study design, an a priori power calculation was not performed. However, with the number of patients available in each arm, the study has 80% power to detect a difference of half an hour in time to reach goal MAP, with a 2-sided alpha of 0.05, assuming a baseline mean of 2 hours with a SD of 0.9 hours to reach goal MAP. In conclusion, there is no difference in the time to reach goal MAP between patients who receive NE <50 µg/min with or without AVP. This AVP-sparing guideline showed little difference in efficacy, safety, and clinical outcomes after adjusting for baseline differences. The guideline revision was associated with decreased mortality after the multivariate regression analysis, although our study was not powered for this outcome. Large, prospective, randomized trials are necessary to identify the dosage of NE at which AVP should be initiated. Declaration of Conflicting Interests The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The authors received no financial support for the research, authorship, and/or publication of this article. References 1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: Crit Care Med. 2013;41: Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107: Micek ST, Shah P, Hollands JM, Shah RA, Shannon WD, Kollef MH. Addition of vasopressin to norepinephrine as independent predictor of mortality in patients with refractory septic shock: an observational study. Surg Infect (Larchmt). 2007;8: Dopp-Zemel D, Groeneveld AB. High-dose norepinephrine treatment: determinants of mortality and futility in critically ill patients. Am J Crit Care. 2013;22: Jenkins CR, Gomersall CD, Leung P, Joynt GM. Outcome of patients receiving high dose vasopressor therapy: a retrospective cohort study. Anaesth Intensive Care. 2009;37:
8 20 Annals of Pharmacotherapy 51(1) 6. Benbenishty J, Weissman C, Sprung CL, Brodsky-Israeli M, Weiss Y. Characteristics of patients receiving vasopressors. Heart Lung. 2011;40: Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358: Stollings J, Mitchell D, Rice T, Wheeler A. An interdisciplinary project to simplify vasopressor use in a medical intensive care unit. Crit Care Med. 2013;41(12): Varpula M, Tallgren M, Saukkonen K, Voipio-Pulkki LM, Pettila V. Hemodynamic variables related to outcome in septic shock. Intensive Care Med. 2005;31: Dunser MW, Takala J, Ulmer H, et al. Arterial blood pressure during early sepsis and outcome. Intensive Care Med. 2009;35: Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med. 2001;27: Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96: Gordon AC, Russell JA, Walley KR, et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med. 2010;36: Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock. JAMA. 2016;316: Luckner G, Dunser MW, Jochberger S, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med. 2005;33: Luckner G, Mayr VD, Jochberger S, et al. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med. 2007;35: Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Lowdose vasopressin in the treatment of vasodilatory septic shock. J Trauma. 1999;47: ; discussion Knotzer H, Maier S, Dunser MW, et al. Arginine vasopressin does not alter mucosal tissue oxygen tension and oxygen supply in an acute endotoxemic pig model. Intensive Care Med. 2006;32: Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med. 2009;37: Bauer SR, Lam SW, Cha SS, Oyen LJ. Effect of corticosteroids on arginine vasopressin-containing vasopressor therapy for septic shock: a case control study. J Crit Care. 2008;23: Torgersen C, Luckner G, Schroder DC, et al. Concomitant arginine-vasopressin and hydrocortisone therapy in severe septic shock: association with mortality. Intensive Care Med. 2011;37: Gordon AC, Mason AJ, Perkins GD, et al. The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med. 2014;42:
EFFECT OF EARLY VASOPRESSIN VS NOREPINEPHRINE ON KIDNEY FAILURE IN PATIENTS WITH SEPTIC SHOCK. Alexandria Rydz
EFFECT OF EARLY VASOPRESSIN VS NOREPINEPHRINE ON KIDNEY FAILURE IN PATIENTS WITH SEPTIC SHOCK Alexandria Rydz BACKGROUND- SEPSIS Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated
More informationVasopressors in Septic Shock. Keith R. Walley, MD St. Paul s Hospital University of British Columbia Vancouver, Canada
Vasopressors in Septic Shock Keith R. Walley, MD St. Paul s Hospital University of British Columbia Vancouver, Canada Echocardiogram: EF=25% 57 y.o. female, pneumonia, shock Echocardiogram: EF=25% 57 y.o.
More informationEvidence-Based. Management of Severe Sepsis. What is the BP Target?
Evidence-Based Management of Severe Sepsis Michael A. Gropper, MD, PhD Professor and Vice Chair of Anesthesia Director, Critical Care Medicine Chair, Quality Improvment University of California San Francisco
More informationWhen options matter. Vasopressor Reloaded. Balance in Haemodynamics - Only Survival Matters
When options matter Vasopressor Reloaded Balance in Haemodynamics - Only Survival Matters Vasopressin Synthesis and Release Physiologic Importance in Septic Shock Hypothalamus Brain Vasopressin deficiency
More informationTaiwan Crit. Care Med.2009;10: C 1. CVP 8~12 mmhg 2. MAP 65 mmhg 1. 1B
6 24 1C 1. CVP 8~12 mmhg 2. MAP 65 mmhg 3. 0.5 ml 4. 70% 65% 1 colloid crystalloid 1B SAFE albumin 2 813 386 07-346-8278 07-350-5220 E-mail shoalin01@.gmail.com 21 p=0.09 prospective meta-analysis 3-5
More informationVOLUME RESPONSIVENESS IS DIFFERENT FROM NEED FOR FLUIDS BLOOD PRESSURE TARGETS IN SEPSIS
Department of Intensive Care Medicine VOLUME RESPONSIVENESS IS DIFFERENT FROM NEED FOR FLUIDS BLOOD PRESSURE TARGETS IN SEPSIS SEPTIC SHOCK : THE CLINICAL SCENARIO HYPOTENSION DESPITE ADEQUATE VOLUME RESUSCITATION
More informationPredictors of response to fixed dose vasopressin in adult patients with septic shock
https://doi.org/10.1186/s13613-018-0379-5 RESEARCH Open Access Predictors of response to fixed dose vasopressin in adult patients with septic shock Gretchen L. Sacha 1*, Simon W. Lam 1, Abhijit Duggal
More informationControversies in Hospital Medicine: Critical Care. Vasopressors, Steroids, and Insulin Therapy
Controversies in Hospital Medicine: Critical Care Vasopressors, Steroids, and Insulin Therapy Douglas Fish, Pharm.D. Professor of Pharmacy, University of Colorado Denver Clinical Specialist in Critical
More informationVasoactive Medications. Matthew J. Korobey Pharm.D., BCCCP Critical Care Clinical Specialist Mercy St. Louis
Vasoactive Medications Matthew J. Korobey Pharm.D., BCCCP Critical Care Clinical Specialist Mercy St. Louis Objectives List components of physiology involved in blood pressure Review terminology related
More information4/5/2018. Update on Sepsis NIKHIL JAGAN PULMONARY AND CRITICAL CARE CREIGHTON UNIVERSITY. I have no financial disclosures
Update on Sepsis NIKHIL JAGAN PULMONARY AND CRITICAL CARE CREIGHTON UNIVERSITY I have no financial disclosures 1 Objectives Why do we care about sepsis Understanding the core measures by Centers for Medicare
More informationShould we use steroids in sepsis? J.G. van der Hoeven
Should we use steroids in sepsis? J.G. van der Hoeven Why I don t like it It is boring.. It usually results in emotional outcries in the audience If any, the effects on outcome are very small You are not
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More informationEarly-goal-directed therapy and protocolised treatment in septic shock
CAT reviews Early-goal-directed therapy and protocolised treatment in septic shock Journal of the Intensive Care Society 2015, Vol. 16(2) 164 168! The Intensive Care Society 2014 Reprints and permissions:
More informationCORTICOSTEROID USE IN SEPTIC SHOCK THE ONGOING DEBATE DIEM HO, PHARMD PGY1 PHARMACY RESIDENT VALLEY BAPTIST MEDICAL CENTER BROWNSVILLE
CORTICOSTEROID USE IN SEPTIC SHOCK THE ONGOING DEBATE DIEM HO, PHARMD PGY1 PHARMACY RESIDENT VALLEY BAPTIST MEDICAL CENTER BROWNSVILLE 1 ABBREVIATIONS ACCP = American College of Chest Physicians ARF =
More informationVasopressors for shock
Vasopressors for shock Background Reviews and Observational Studies Holler 2015. Nontraumatic Hypotension and Shock in the Emergency Department and Prehospital Setting Prevalence, Etiology and Mortality:
More informationObjectives. Management of Septic Shock. Definitions Progression of sepsis. Epidemiology of severe sepsis. Major goals of therapy
Objectives Management of Septic Shock Review of the Evidence and Implementation of Pediatric Guidelines at Christus Santa Rosa Manish Desai, M.D. PL 5 2 nd year Pediatric Critical Care Fellow Review of
More informationJohn Park, MD Assistant Professor of Medicine
John Park, MD Assistant Professor of Medicine Faculty photo will be placed here park.john@mayo.edu 2015 MFMER 3543652-1 Sepsis Out with the Old, In with the New Mayo School of Continuous Professional Development
More informationAddition of vasopressin to norepinephrine as independent predictor of mortality in patients with refractory septic shock: An observational study
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2007 Addition of vasopressin to norepinephrine as independent predictor of mortality in patients with refractory
More informationFluids in Sepsis: How much and what type? John Fowler, MD, FACEP Kent Hospital, İzmir Eisenhower Medical Center, USA American Hospital Dubai, UAE
Fluids in Sepsis: How much and what type? John Fowler, MD, FACEP Kent Hospital, İzmir Eisenhower Medical Center, USA American Hospital Dubai, UAE In critically ill patients: too little fluid Low preload,
More informationSurviving Sepsis Campaign Guidelines 2012 & Update for David E. Tannehill, DO Critical Care Medicine Mercy Hospital St.
Surviving Sepsis Campaign Guidelines 2012 & Update for 2015 David E. Tannehill, DO Critical Care Medicine Mercy Hospital St. Louis Be appropriately aggressive the longer one delays aggressive metabolic
More informationSepsis is a complicated infectious process that propagates. Use of Vasopressors in Septic Shock. Clinical review
Use of Vasopressors in Septic Shock Megan A. Rech, PharmD, Megan Prasse, PharmD, and Gourang Patel, PharmD, MSc Abstract Objective: To review the latest findings on the use of vasopressor agents in septic
More informationAcute Liver Failure: Supporting Other Organs
Acute Liver Failure: Supporting Other Organs Michael A. Gropper, MD, PhD Professor of Anesthesia and Physiology Director, Critical Care Medicine University of California San Francisco Acute Liver Failure
More informationStaging Sepsis for the Emergency Department: Physician
Staging Sepsis for the Emergency Department: Physician Sepsis Continuum 1 Sepsis Continuum SIRS = 2 or more clinical criteria, resulting in Systemic Inflammatory Response Syndrome Sepsis = SIRS + proven/suspected
More informationFew clinical trials have directly
CLNCAL CONSULTATON CLNCAL CONSULTATON for vasopressor-dependent septic shock PAUL M. SZUMTA, CHRSTOPHER M. ENFANTO, BONNE GREENWOO, AN MCHAEL E. WECHSLER The Clinical Consultation column provides brief
More informationCardiovascular Management of Septic Shock
Cardiovascular Management of Septic Shock R. Phillip Dellinger, MD Professor of Medicine Robert Wood Johnson Medical School/UMDNJ Director, Critical Care Medicine and Med/Surg ICU Cooper University Hospital
More informationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 Mitchell M. Levy MD, MCCM Professor of Medicine Chief, Division of Pulmonary, Sleep, and Critical Care
More informationThe Art and Science of Infusion Nursing John M. Allen, PharmD, BCPS. Understanding Vasoactive Medications
The Art and Science of Infusion Nursing John M. Allen, PharmD, BCPS Understanding Vasoactive Medications Focus on Pharmacology and Effective Titration ABSTRACT In the care of the critically ill patient,
More informationThe Use of Metabolic Resuscitation in Sepsis
The Use of Metabolic Resuscitation in Sepsis Jennifer M. Roth, PharmD, BCPS, BCCCP Critical Care Clinical Specialist - Surgical Trauma ICU Baylor University Medical Center Disclosures No conflicts of interest
More informationSepsis is an important issue. Clinician s decision-making capability. Guideline recommendations
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012 Clinicians decision-making capability Guideline recommendations Sepsis is an important issue 8.7%
More informationINTENSIVE CARE MEDICINE CPD EVENING. Dr Alastair Morgan Wednesday 13 th September 2017
INTENSIVE CARE MEDICINE CPD EVENING Dr Alastair Morgan Wednesday 13 th September 2017 WHAT IS NEW IN ICU? (RELEVANT TO ANAESTHETISTS) Not much! SURVIVING SEPSIS How many deaths in England were thought
More informationIs nosocomial infection the major cause of death in sepsis?
Is nosocomial infection the major cause of death in sepsis? Warren L. Lee, MD PhD, FRCPC Department of Medicine University of Toronto There are no specific therapies for sepsis the graveyard for pharmaceutical
More informationCase year old female nursing home resident with a hx CAD, PUD, recent hip fracture Transferred to ED with decreased mental status BP in ED 80/50
Case 1 65 year old female nursing home resident with a hx CAD, PUD, recent hip fracture Transferred to ED with decreased mental status BP in ED 80/50 Case 1 65 year old female nursing home resident with
More informationBC Sepsis Network Emergency Department Sepsis Guidelines
The provincial Sepsis Clinical Expert Group developed the BC, taking into account the most up-to-date literature (references below) and expert opinion. For more information about the guidelines, and to
More informationUpdate in Critical Care Medicine
Update in Critical Care Medicine Michael A. Gropper, MD, PhD Professor and Executive Vice Chair Department of Anesthesia and Perioperative Care Director, Critical Care Medicine UCSF Disclosure None Update
More informationSepsis: Identification and Management in an Acute Care Setting
Sepsis: Identification and Management in an Acute Care Setting Dr. Barbara M. Mills DNP Director Rapid Response Team/ Code Resuscitation Stony Brook University Medical Center SEPSIS LECTURE NPA 2018 OBJECTIVES
More information6/5/2014. Sepsis Management and Hemodynamics. 2004: International group of experts,
Sepsis Management and Hemodynamics Javier Perez-Fernandez, M.D., F.C.C.P. Medical Director Critical Care Services, Baptist t Hospital of Miamii Medical Director Pulmonary Services, West Kendall Baptist
More informationEffects of combined vasopressin-noradrenaline in pediatric patients with refractory septic shock
Effects of combined vasopressin-noradrenaline in pediatric patients with refractory septic shock J. A. Fernandez 1, A. C. Sepúlveda 2, M. Salas 2, PA Lopez 3, S. J. Olarte 2 1 Pediatric Critical Care Department,
More informationSepsis and Hemodynamic Support in September 15, 2017 Carleen Risaliti
Sepsis and Hemodynamic Support in 2017 September 15, 2017 Carleen Risaliti Objectives Review fluid resuscitation guidelines in septic shock Discuss volume assessment v. fluid responsiveness Evaluate pros
More informationDESIGNER RESUSCITATION: TITRATING TO TISSUE NEEDS
DESIGNER RESUSCITATION: TITRATING TO TISSUE NEEDS R. Phillip Dellinger MD, MSc, MCCM Professor and Chair of Medicine Cooper Medical School of Rowan University Chief of Medicine Cooper University Hospital
More informationThe Pharmacology of Hypotension: Vasopressor Choices for HIE patients. Keliana O Mara, PharmD August 4, 2018
The Pharmacology of Hypotension: Vasopressor Choices for HIE patients Keliana O Mara, PharmD August 4, 2018 Objectives Review the pathophysiology of hypotension in neonates Discuss the role of vasopressors
More informationSwans and Pressors. Vanderbilt Surgery Summer School Ricky Shinall
Swans and Pressors Vanderbilt Surgery Summer School Ricky Shinall Shock, Swans, Pressors in 15 minutes 4 Reasons for Shock 4 Swan numbers to know 7 Pressors =15 things to know 4 Reasons for Shock Not enough
More informationNothing to disclose 9/25/2017
Jessie O Neal, PharmD, BCCCP Critical Care Clinical Pharmacist University of New Mexico Hospital New Mexico Society of Health-System Pharmacists 2017 Balloon Fiesta Symposium Nothing to disclose 1 Explain
More informationVasopressors in septic shock
Vasopressors in septic shock Prof. Jean-Louis TEBOUL Medical ICU Bicetre hospital University Paris-South France Questions 1- Why do we use vasopressors in septic shock? 2- Which first-line agent? 3- When
More information9/25/2017. Nothing to disclose
Nothing to disclose Jessie O Neal, PharmD, BCCCP Critical Care Clinical Pharmacist University of New Mexico Hospital New Mexico Society of Health-System Pharmacists 2017 Balloon Fiesta Symposium Explain
More informationSwans and Pressors. Vanderbilt Surgery Summer School Ricky Shinall
Swans and Pressors Vanderbilt Surgery Summer School Ricky Shinall SHOCK Hypotension SHOCK Hypotension SHOCK=Reduction of systemic tissue perfusion, resulting in decreased oxygen delivery to the tissues.
More informationTitrating Critical Care Medications
Titrating Critical Care Medications Chad Johnson, MSN (NED), RN, CNCC(C), CNS-cc Clinical Nurse Specialist: Critical Care and Neurosurgical Services E-mail: johnsoc@tbh.net Copyright 2017 1 Learning Objectives
More informationPEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to
More informationFluid Resuscitation and Monitoring in Sepsis. Deepa Gotur, MD, FCCP Anne Rain T. Brown, PharmD, BCPS
Fluid Resuscitation and Monitoring in Sepsis Deepa Gotur, MD, FCCP Anne Rain T. Brown, PharmD, BCPS Learning Objectives Compare and contrast fluid resuscitation strategies in septic shock Discuss available
More informationSepsis overview. Dr. Tsang Hin Hung MBBS FHKCP FRCP
Sepsis overview Dr. Tsang Hin Hung MBBS FHKCP FRCP Epidemiology Sepsis, severe sepsis, septic shock Pathophysiology of sepsis Recent researches and advances From bench to bedside Sepsis bundle Severe sepsis
More informationENDPOINTS FOR AKI STUDIES
ENDPOINTS FOR AKI STUDIES Raymond Vanholder, University Hospital, Ghent, Belgium SUMMARY! AKI as an endpoint! Endpoints for studies in AKI 2 AKI AS AN ENDPOINT BEFORE RIFLE THE LIST OF DEFINITIONS WAS
More informationPharmacology of inotropes and vasopressors
Pharmacology of inotropes and vasopressors Curriculum 3.3 Recognises and manages the patient with circulatory failure 4.4 Uses fluids and vasoactive / inotropic drugs to support the circulation PR_BK_41
More informationSurviving Sepsis. Brian Woodcock MBChB MRCP FRCA FCCM
1 Surviving Sepsis Brian Woodcock MBChB MRCP FRCA FCCM 2 Disclosures No conflicts of interest 3 Sepsis Principles of management of septic shock in the operating room "Surviving Sepsis" guidelines 4 Add-on
More informationSerum potassium levels and outcomes in critically ill patients in the medical intensive care unit
Clinical Report Serum potassium levels and outcomes in critically ill patients in the medical intensive care unit Journal of International Medical Research 2018, Vol. 46(3) 1254 1262! The Author(s) 2018
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for
More informationShould Roids Be the Rage in Septic Shock? Lauren Powell, MSN, RN, CCRN, AGACNP-BC CHI Baylor St. Luke s Medical Center, Houston, TX
Should Roids Be the Rage in Septic Shock? Lauren Powell, MSN, RN, CCRN, AGACNP-BC CHI Baylor St. Luke s Medical Center, Houston, TX Learning Objectives 1. Review the mechanism of action for the use of
More informationPediatric Septic Shock. Geoffrey M. Fleming M.D. Division of Pediatric Critical Care Vanderbilt University School of Medicine Nashville, Tennessee
Pediatric Septic Shock Geoffrey M. Fleming M.D. Division of Pediatric Critical Care Vanderbilt University School of Medicine Nashville, Tennessee Case 4 year old male with a history of gastroschesis repaired
More informationSeptic Shock. Rontgene M. Solante, MD, FPCP,FPSMID
Septic Shock Rontgene M. Solante, MD, FPCP,FPSMID Learning Objectives Identify situations wherein high or low BP are hemodynamically significant Recognize complications arising from BP emergencies Manage
More informationDiagnosis and Management of Sepsis and Septic Shock. Martin D. Black MD Concord Pulmonary Medicine Concord, New Hampshire
Diagnosis and Management of Sepsis and Septic Shock Martin D. Black MD Concord Pulmonary Medicine Concord, New Hampshire Financial: none Disclosures Objectives: Identify physiologic principles of septic
More informationSepsis Management: Past, Present, and Future
Sepsis Management: Past, Present, and Future Benjamin Ferrell, MD Tennessee ACP Meeting October 28, 2017 Learning Objectives Identify the most updated definition and clinical criteria for sepsis Describe
More informationActualités de la prise en charge hémodynamique initiale Daniel De Backer
Actualités de la prise en charge hémodynamique initiale Daniel De Backer Head Dept Intensive Care, CHIREC hospitals, Belgium Professor of Intensive Care, Université Libre de Bruxelles Past- President European
More informationWhat works in sepsis. Topics. EGDT: Severe Sepsis/ Shock. Sepsis
What works in sepsis Eric Schmidt, MD Denver Health Medical Center University of Colorado School of Medicine Topics Understanding and implemen@ng early goal directed therapy (EGDT) Ac@vated Protein C should
More informationVasopressor hormones in shock noradrenaline, vasopressin or angiotensin II: which one will make the race?
Editorial Vasopressor hormones in shock noradrenaline, vasopressin or angiotensin II: which one will make the race? Martin W. Dünser 1, Jens Meier 2 1 Department of Critical Care, University College of
More informationAccepted Manuscript. Mitchell S. Buckley, Robert MacLaren. S (17)30641-X doi: /j.jcrc Reference: YJCRC
Accepted Manuscript Concomitant vasopressin and hydrocortisone therapy on shortterm hemodynamic effects and vasopressor requirements in refractory septic shock Mitchell S. Buckley, Robert MacLaren PII:
More informationBack to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
More informationTop Sepsis Studies
A75M233/A75M529 Monday 08:00-09:15 Wednesday 14:45-16:00 Maureen A Seckel APRN, ACNS-BC, CCRN, CCNS, FCCM Critical Care CNS and Sepsis Leader Christiana Care Health Services, Newark, DE Top Sepsis Studies
More informationWhen Fluids are Not Enough: Inopressor Therapy
When Fluids are Not Enough: Inopressor Therapy Problems in Neonatology Neonatal problem: hypoperfusion Severe sepsis Hallmark of septic shock Secondary to neonatal encephalopathy Vasoplegia Syndrome??
More informationThe Ever Changing World of Sepsis Management. Laura Evans MD MSc Medical Director of Critical Care Bellevue Hospital
The Ever Changing World of Sepsis Management Laura Evans MD MSc Medical Director of Critical Care Bellevue Hospital COI Disclosures No financial interests to disclose Learning Objectives Review the evolution
More informationFacilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Care Unit (FELLOW)
Facilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Data Analysis Plan: Apneic Oxygenation vs. No Apneic Oxygenation Background Critically ill patients
More informationSteroid in Paediatric Sepsis. Dr Pon Kah Min Hospital Pulau Pinang
Steroid in Paediatric Sepsis Dr Pon Kah Min Hospital Pulau Pinang Contents Importance of steroid in sepsis Literature Review for adult studies Literature Review for paediatric studies Conclusions. Rationale
More informationSepsis Early Recognition and Management. Therese Hughes, PhD, MPA, RN
Sepsis Early Recognition and Management Therese Hughes, PhD, MPA, RN 1 Sepsis a Deadly Progression Affects millions around the world each year, killing one in four Contributes to approximately 50% of all
More informationEarly Goal Directed Therapy in 2015: What Did the Big Trials Teach us?
Early Goal Directed Therapy in 2015: What Did the Big Trials Teach us? Mitchell M. Levy MD, FCCM Professor of Medicine Chief, Division of Pulmonary, Sleep, and Critical Care Warren Alpert Medical School
More informationOHSU. Update in Sepsis
Update in Sepsis Jonathan Pak, MD June 1, 2017 Structure of Talk 1. Sepsis-3: The latest definition 2. Clinical Management - Is EGDT dead? - Surviving Sepsis Campaign Guidelines 3. A novel therapy: Vitamin
More informationSepsis Bundle Project (SEP) Kathy Wonderly RN, MSEd, CPHQ Consultant Developed: April 2015 Most recent Revision: December 2018
Sepsis Bundle Project (SEP) Kathy Wonderly RN, MSEd, CPHQ Consultant Developed: April 2015 Most recent Revision: December 2018 Objectives 1. To identify the symptom of severe sepsis and septic shock syndrome.
More informationWhen Fluids are Not Enough: Inopressor Therapy
When Fluids are Not Enough: Inopressor Therapy Problems in Neonatology Neonatal problem: hypoperfusion Severe sepsis Hallmark of septic shock Secondary to neonatal encephalopathy Vasoplegia Syndrome??
More informationDilemmas in Septic Shock
Dilemmas in Septic Shock William Janssen, M.D. Assistant Professor of Medicine National Jewish Health University of Colorado Denver Health Sciences Center A 62 year-old female presents to the ED with fever,
More informationUseful diagnostic measures: chest x ray to check pulmonary edema, ECG and ECHO to detect cardiac abnormalities (1).
Cardiogenic shock Etiology The most common cause of cardiogenic shock is LV dysfunction and necrosis as a result of acute myocardial infarction (AMI) (1). Acute valvular insufficiency or stenosis prevents
More informationMaking vasopressors safer
Making vasopressors safer Requirements for safe vaspressor use In an ideal world 1. Knowledge of what constitutes optimal vasopressor dosing 2. A culture of cautiousness regarding vasopressors What do
More informationR2R: Severe sepsis/septic shock. Surat Tongyoo Critical care medicine Siriraj Hospital
R2R: Severe sepsis/septic shock Surat Tongyoo Critical care medicine Siriraj Hospital Diagnostic criteria ACCP/SCCM consensus conference 1991 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
More informationSepsis Story At Intermountain Healthcare Intensive Medicine Clinical Program
Sepsis Story At Intermountain Healthcare 2004-2012 Intensive Medicine Clinical Program The International Surviving Sepsis Campaign Was Organized In 2002 During The ESICM International Meeting In Barcelona,
More informationΔακτυλίτιδα και Ινότροπα Φάρμακα στην Καρδιακή Ανεπάρκεια. Ι.Κανονίδης
Δακτυλίτιδα και Ινότροπα Φάρμακα στην Καρδιακή Ανεπάρκεια Ι.Κανονίδης Cardiac Glycosides Chronic Congestive Heart Failure DIGOXIN Na-K ATPase Na + K + Na-Ca Exchange Na + Ca ++ Ca ++ K + Na + Myofilaments
More informationSEPSIS 2015 DISCLOSURES FINANCIAL DISCLOSURES 9/1/2015. William M. Johnson, MD Nebraska Pulmonary Specialties. William Johnson
SEPSIS 2015 William M. Johnson, MD Nebraska Pulmonary Specialties 1 DISCLOSURES William Johnson No financial interests related to this presentation 2 FINANCIAL DISCLOSURES I do however have 3 children
More informationJames A. Russell 1,2*, Hugh Wellman 3 and Keith R. Walley 1,2
Russell et al. Journal of Intensive Care (2018) 6:73 https://doi.org/10.1186/s40560-018-0344-2 RESEARCH Open Access Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency
More informationUtilizing Vasopressors:
Utilizing Vasopressors: Critical Care Advances in the Emergency Department José A. Rubero, MD, FACEP, FAAEM Associate Program Director University of Central Florida/HCA GME Consortium Emergency Medicine
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationNE refractoriness: From Definition To Treatment... Prof. Alain Combes
NE refractoriness: From Definition To Treatment... Prof. Alain Combes Service de Réanimation ican, Institute of Cardiometabolism and Nutrition Hôpital Pitié-Salpêtrière, AP-HP, Paris Université Pierre
More informationManagement of Severe Sepsis:
Management of Severe Sepsis: Update from the Surviving Sepsis Campaign Barbara Birriel, MSN, ACNP-BC, FCCM The Pennsylvania State University NONE Disclosures Review evidence-based international sepsis
More informationImpact of Fluids in Children with Acute Lung Injury
Impact of Fluids in Children with Acute Lung Injury Canadian Critical Care Forum Toronto, Canada October 27 th, 2015 Adrienne G. Randolph, MD, MSc Critical Care Division, Department of Anesthesia, Perioperative
More informationObjectives. Epidemiology of Sepsis. Review Guidelines for Resuscitation. Tx: EGDT, timing/choice of abx, activated
Update on Surviving Sepsis 2008 Objectives Epidemiology of Sepsis Definition of Sepsis and Septic Shock Review Guidelines for Resuscitation Dx: Lactate, t cultures, SVO2 Tx: EGDT, timing/choice of abx,
More informationSHOCK. Emergency pediatric PICU division Pediatric Department Medical Faculty, University of Sumatera Utara H. Adam Malik Hospital
SHOCK Emergency pediatric PICU division Pediatric Department Medical Faculty, University of Sumatera Utara H. Adam Malik Hospital 1 Definition Shock is an acute, complex state of circulatory dysfunction
More informationEARLY GOAL DIRECTED THERAPY : seminaires iris. Etat des lieux en Daniel De Backer
EARLY GOAL DIRECTED THERAPY : Etat des lieux en 2017 Daniel De Backer Head Dept Intensive Care, CHIREC hospitals, Belgium Professor of Intensive Care, Université Libre de Bruxelles Past-President European
More informationSepsis Management Update 2014
Sepsis Management Update 2014 Laura J. Moore, MD, FACS Associate Professor, Department of Surgery The University of Texas Health Science Center, Houston Medical Director, Shock Trauma ICU Texas Trauma
More informationThe ARREST Trial: Amiodarone for Resuscitation After Out-of-Hospital Cardiac Arrest Due to Ventricular Fibrillation
The ARREST Trial: Amiodarone for Resuscitation After Out-of-Hospital Cardiac Arrest Due to Ventricular Fibrillation Introduction The ARREST (Amiodarone in out-of-hospital Resuscitation of REfractory Sustained
More informationSupplementary Online Content
Supplementary Online Content Andrews B, Semler MW, Muchemwa L, et al. Effect of an early resuscitation protocol on in-hospital mortality among adults with sepsis and hypotension: a randomized clinical
More informationExclusion Criteria 1. Operator or supervisor feels specific intra- procedural laryngoscopy device will be required.
FELLOW Study Data Analysis Plan Direct Laryngoscopy vs Video Laryngoscopy Background Respiratory failure requiring endotracheal intubation occurs in as many as 40% of critically ill patients. Procedural
More informationThe subject of the best vasopressor drug for the initial
Implementation of a Norepinephrine-based Protocol for Management of Septic Shock: A Pilot Feasibility Study Glenn Hernandez, MD, Alejandro Bruhn, MD, Carlos Romero, MD, Francisco Javier Larrondo, MS, Rene
More informationPatient Safety Safe Table Webcast: Sepsis (Part III and IV) December 17, 2014
Patient Safety Safe Table Webcast: Sepsis (Part III and IV) December 17, 2014 Presenters Mark Blaney, RN Regional Nurse Educator CHI Franciscan Health Karen Lautermilch Director, Quality & Performance
More informationObjectives. Outline. Sepsis Incidence and Outcomes. Definitions
Objectives Evaluate recent literature on the management of sepsis Apply new and potentially controversial recommendations from the Surviving Sepsis Guidelines to patient cases. Surviving Sepsis Campaign
More informationPediatric Sepsis Treatment:
Disclosures Pediatric Sepsis Treatment: (treat) Early & (reevaluate) Often None June 11, 2018 Leslie Dervan, MD MS Pacific Northwest Sepsis Conference 1 Agenda Sepsis: pathophysiology at-a-glance Pediatric
More informationInfectious Diseases II
Simon W. Lam, Pharm.D., FCCM, BCPS Cleveland Clinic Cleveland, Ohio Seth R. Bauer, Pharm.D., FCCM, BCPS Cleveland Clinic Cleveland, Ohio Infectious Diseases II Simon W. Lam, Pharm.D., FCCM, BCPS Cleveland
More informationAcute Kidney Injury for the General Surgeon
Acute Kidney Injury for the General Surgeon UCSF Postgraduate Course in General Surgery Maui, HI March 20, 2011 Epidemiology & Definition Pathophysiology Clinical Studies Management Summary Hobart W. Harris,
More information